TERT promoter mutated circulating tumor DNA as a biomarker for prognosis in hepatocellular carcinoma.

Background And Aims: Plasma circulating tumor DNA (ctDNA) with tumor-specific mutations is an attractive biomarker. The telomerase reverse transcriptase () C228T promoter mutation is the most prevalent tumor-associated mutation in hepatocellular carcinoma (HCC). We evaluated the presence and prognostic value of the C228T mutation in plasma and tissue in a Danish HCC cohort.

[Hypoglycaemia after gastric bypass is a challenge to diagnostic procedures and treatment].

Treatment of severe obesity by Roux-en-Y gastric bypass (RYGB) causes sustained weight losses and improves health complica-tions. RYGB is, however, also associated with adverse effects. Dumping is a well-known complication causing invalidating symptoms, and lately there have been mounting concerns about post-RYGB hypoglycaemia.